IgA nephropathy (IgAN), also called Berger’s disease, is a type of glomerulonephritis. Glomerulonephritis is inflammation of the glomeruli – the blood vessels in the kidneys that filter wastes and excess fluids from the blood and excrete them in the urine.
For people with IgA nephropathy, the antibody called immunoglobulin A (IgA) is abnormal causing it to accumulate in the blood. The abnormal IgA is recognized by the immune system and antibodies are formed against it resulting in immune complexes. These immune complexes are deposited in the center of the kidneys’ glomeruli causing cellular changes within the glomeruli, including inflammation and scarring. These changes damage the glomerular filtration barrier, causing blood and protein to leak into the urine. Over time, this damage to the kidneys’ filtering capability can lead to end-stage kidney disease, also called kidney failure.
Between 30-40% of people with IgA nephropathy are diagnosed with visible hematuria (blood in the urine that may make the urine look like tea or cola).1 Another 30-40% of people are diagnosed without any symptoms, when standard urine testing reveals proteinuria (protein that has leaked into the urine) and microscopic hematuria.1 The remainder are diagnosed later in life when the disease may have already progressed, with symptoms of proteinuria, high blood pressure, swelling (edema) and low levels of protein in the blood (hypoalbuminemia).1 A definitive diagnosis typically requires blood and urine tests and a kidney biopsy.
Disease progression can be slow and varies considerably among populations.2,3
Treatment aims to reduce proteinuria to less than 1 g/day and reduce blood pressure which is important for long-term preservation of kidney function.
IgA nephropathy frequently occurs in adolescence or early adulthood, usually in the second and third decades of life.1 Estimated incidence of IgA nephropathy is 2.5 per 100,000 individuals per year among adults4, with geographic, racial and ethnic variations in prevalence.1,5 Prevalence of IgA nephropathy may be higher in individuals of Pacific Asian and southern European descent versus those of North American and northern European descent.1,6 In the US, IgA nephropathy is the most common primary glomerular disease in young Caucasian adults.6 The rare kidney disease is the most common type of primary glomerulonephritis worldwide.
Learn more about about the mechanisms of disease in FSGS and IgAN, and understand disease progression.
Visit the Travere Medical Affairs website for our latest publications, medical congress presentations, podcasts, medical information resources, and more for U.S. healthcare professionals.
Jeff
After his unexpected IgAN diagnosis, Jeff found strength in his community and care team—empowering him to take control of his health and raise awareness for others facing rare kidney disease.
Stephanie
From avid hiker to kidney failure survivor, Stephanie’s journey with IgAN and FSGS has been one of resilience, community, and hope. See how her family and support network have helped her move forward.
Stuart
After a decade with IgAN, Stuart’s kidney function declined—until a lifesaving donation from his wife changed everything. Now, he’s giving back through advocacy. Watch his story.
Gisela
From a long wait for answers to finding hope through a kidney transplant, Gisela’s journey with IgAN has been one of resilience and advocacy. Now, she’s helping others navigate their own path.
Lillie
Lillie’s rare kidney disease doesn’t define her—she’s a dancer, an advocate, and a voice for change. See how she and her mom, Carrie, are educating, empowering, and pushing for progress.
Kate
After her diagnosis, Kate sought the right expert for her care and began to feel a sense of peace, recognizing that a good life is still possible even after her IgAN diagnosis.